Issue 126 • January 2023
In association with
Humira biosimilars set the stage for long-awaited 2023 US launches
After much buzz, the entry of Humira biosimilars is being seen as a major cost-cutting opportunity, but market penetration will not be instant
In association with
Issue 126
Brought to you by
